Bispecific Antibody Purification: Insights And Case Studies

By David Westman, Global Marketing Manager Antibody Downstream

The biopharma pipeline is changing. As we move from a mAb-focused industry, new challenges arise with the increased diversification of therapeutic molecules. One of these new types of molecules are bispecific antibodies (BsAbs). This group has several advantages over mAbs. But it also presents unique process development issues to solve.

Bispecific antibodies interact with two different surface antigens. This dual specificity enables a wide range of applications, like blocking two different signaling pathways simultaneously. Today there are three commercially approved therapeutic BsAbs, about 80 in clinical trials, and many more in the preclinical phase.

For purification, there’s not just one right answer to which strategy to use. Here are some industry insights to help you navigate the bispecific jungle.